Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Grifols International
Deal Size : $6.2 million
Deal Type : Acquisition
Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.
Details : Grifols, S.A.will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : $3.2 million
February 21, 2020
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Grifols International
Deal Size : $6.2 million
Deal Type : Acquisition
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 04, 2014
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 23, 2012
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable